Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.

待确认 10 由 Aixuexi 发布于 2026/10/12 16:22:53

DOI:10.1093/jnci/djaf220
作者：Paolo Tarantino,Do Lee,Julia Foldi,Pamela R Soulos,Cary P Gross,Tess O'Meara,Thomas Grinda,Stefania Morganti,Adrienne G Waks,Eric P Winer,Nancy U Lin,Ian E Krop,Sara M Tolaney,Sarah Sammons,Maryam Lus
文献类型：期刊论文
补充材料：只需要正文

Oxford University Press

Abstract：BACKGROUND Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available to guide treatment after exposure to T-DXd

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

16小时前

llww

202610121631095938930.pdf

16小时前

Book学术机器人

2026/10/12 16:22:54 未找到该文献，机器人已退出，请等待人工下载

2026/10/12 16:22:53 Book学术AI机器人收到请求，开始寻找文献

2026/10/12 16:22:53 已向机器人发送请求

16小时前

Aixuexi 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:JSTORAesthetic Education: Some Strategies for Intervention